Inovio reports Q2 EPS (61c), consensus (62c)

“With device DV testing complete, we remain on track to submit our BLA for INO-3107 in the second half of this year, with the goal of having FDA acceptance of the file by year end. Utilizing our breakthrough therapy designation, we’ve requested rolling submission and expect to be able to immediately provide the clinical and non-clinical modules for review, while we complete work on the device-related sections and update our Investigational New Drug Application for our confirmatory trial,” said Dr. Jacqueline Shea, INOVIO’s (INO) President and Chief Executive Officer. “We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis patients and their physicians-a treatment option with the potential to change the trajectory of this disease. I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.” INOVIO estimates its current cash, cash equivalents and short-term investments balances, including the net proceeds from the July 2025 offering, will support the company’s operations into the second quarter of 2026. This projection includes an operational net cash burn estimate of approximately $22M for the third quarter of 2025. These projections do not include any further capital-raising activities that INOVIO may undertake.